Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2021-04-08 Regulatory Filings
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from a company's legal counsel to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a Draft Registration Statement on Form S-1. The letter addresses specific SEC comments on disclosures, revisions to the prospectus, and clarifications related to the company's registration statement for an initial public offering (IPO). It references the Form S-1 registration process, which is used for securities offerings, and discusses revisions to the public registration statement. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on a registration statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which includes compliance documents and miscellaneous filings that do not fit other categories.
2021-04-08 English
S-1
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock by Werewolf Therapeutics, Inc. The document includes detailed information about the company, its business, risk factors, management, financial data, and the offering itself. Form S-1 is a standard SEC filing used for registration of securities for public offering and is not an annual report, earnings release, or any other type of report listed in the classification scheme. The closest relevant category for this type of document, which is a registration statement for securities offering, is not explicitly listed among the provided categories. However, since it is a regulatory filing related to securities registration and offering, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2021-04-08 English
Regulatory Filings 2021
Regulatory Filings
2021-03-29 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC, dated February 26, 2021. It is a preliminary prospectus for an initial public offering (IPO) of common stock by Werewolf Therapeutics, Inc. The text includes detailed information about the company, the offering, risk factors, management discussion and analysis, executive compensation, and other disclosures typical of an IPO registration statement. This type of filing is related to capital raising and securities registration under the Securities Act of 1933. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). The Form S-1 is not an annual or quarterly report, nor is it a proxy, earnings release, or other category. Therefore, the correct classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual registration statement, not just an announcement of it.
2021-02-26 English
Regulatory Filings 2021
Regulatory Filings
2021-01-07 English
Regulatory Filings 2020
Regulatory Filings
2020-08-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.